Singapore, April 23 -- Japan-based Global Health Innovative Technology (GHIT) Fund has announced an investment of approximatelyJPY 679 million($4.5 million) for the development of diagnostics for tuberculosis (TB); in addition to an investment of approximatelyJPY 15.9 million($0.1 million) for a drug discovery project for Chagas disease and leishmaniasis (by Kitasato University,NagasakiUniversity,University of Tokyo, and Drugs for Neglected Diseases initiative (DNDi).

The $4.5 million funding is towards a new TB diagnostic development project by US-based diagnostic developer Fluxus, Inc.,in partnership with Fujirebio, Inc., a developer of clinical diagnostics inJapan,andHeidelberg University Hospital inGermany.

This project will leverag...